Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →2seventy bio today reported preliminary full-year 2024 U.S. Abecma revenue of approximately $242 million, within the guidance range of $240 to $250 million…
Bristol Myers Squibb is stepping in to buy its Abecma partner 2seventy bio for $286 million, ending the biotech's tumultuous journey as a singular…
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb. The company provided an update on the…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
BMS agreed to acquire 2seventy bio for $5.00/share in all-cash transaction, total equity value ~$286M, representing an 88% premium. Consolidates full ownership of Abecma CAR-T therapy previously co-developed with 2seventy under a profit-share arrangement.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / 2seventy bio, Inc. (this deal) | 2025 | $286M | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2025 deals · Bristol-Myers Squibb Company deals · Hematology deals